301331 Stock Overview
Enwei Pharmaceutical Co., Ltd. develops and sells Chinese medicines in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Enwei Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥38.03 |
| 52 Week High | CN¥51.79 |
| 52 Week Low | CN¥27.95 |
| Beta | 0 |
| 1 Month Change | 8.01% |
| 3 Month Change | -0.34% |
| 1 Year Change | -6.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301331 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.4% | 4.9% | 2.1% |
| 1Y | -6.8% | -13.4% | -14.2% |
Return vs Industry: 301331 exceeded the CN Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 301331 exceeded the CN Market which returned -14.6% over the past year.
Price Volatility
| 301331 volatility | |
|---|---|
| 301331 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 301331 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301331's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,610 | Yongjiang Xue | www.enwei.com.cn |
Enwei Pharmaceutical Co., Ltd. develops and sells Chinese medicines in China. It offers drugs in the areas of gynecology, pediatrics, respiratory system, and other pharmaceutical fields. The company was founded in 2005 and is based in Chengdu, China.
Enwei Pharmaceutical Co., Ltd. Fundamentals Summary
| 301331 fundamental statistics | |
|---|---|
| Market cap | CN¥2.67b |
| Earnings (TTM) | CN¥67.07m |
| Revenue (TTM) | CN¥767.87m |
39.8x
P/E Ratio3.5x
P/S RatioIs 301331 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301331 income statement (TTM) | |
|---|---|
| Revenue | CN¥767.87m |
| Cost of Revenue | CN¥379.85m |
| Gross Profit | CN¥388.02m |
| Other Expenses | CN¥320.95m |
| Earnings | CN¥67.07m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.96 |
| Gross Margin | 50.53% |
| Net Profit Margin | 8.73% |
| Debt/Equity Ratio | 3.2% |
How did 301331 perform over the long term?
See historical performance and comparison